CVS Health delivered one of the strongest quarters the managed-care industry has seen in years, surpassing $100 billion in quarterly revenue, raising full-year earnings guidance and signaling that one of Wall Street’s most battered healthcare giants may finally be stabilizing after two years of rising medical costs and investor skepticism.
The healthcare and pharmacy conglomerate reported Wednesday that first-quarter revenue rose 6.2% year over year to $100.4 billion, with growth across all three major operating divisions. The company simultaneously lifted its full-year 2026 adjusted earnings forecast to $7.30 to $7.50 per share, up from prior guidance of $7.00 to $7.20, while increasing projected operating cash flow to at least $9.5 billion.
For investors, the numbers represented something the sector has struggled to produce consistently since the pandemic: operational stability.
Adjusted earnings per share came in at $2.57, while GAAP diluted EPS totaled $2.30. Operating income surged 38.7%, helped partly by the absence of major one-time charges that weighed on results a year earlier, including a $387 million litigation expense and a $247 million pre-tax loss tied to the wind-down of certain accountable-care assets.
More importantly for Wall Street, adjusted operating income still rose a healthy 12.5%, driven largely by improvement inside the company’s insurance business.
That segment — the Aetna Health Care Benefits division — had become the focal point of investor anxiety throughout 2024 and early 2025 as Medicare Advantage utilization, post-pandemic healthcare demand and surging GLP-1 drug costs pressured profitability across the entire managed-care sector.
Industry rivals including UnitedHealth Group, Humana, Elevance Health and Centene all spent portions of the past two years cutting guidance, rebuilding reserves and attempting to reassure investors that medical-cost inflation remained manageable.
CVS itself underwent a major leadership shakeup after replacing former chief executive Karen Lynch in late 2024 with longtime executive David Joyner, who has since aggressively restructured pricing, pharmacy-benefit operations and the company’s sprawling healthcare footprint.
Wednesday’s results suggest those efforts are beginning to gain traction.
Pharmacy claims inside the Health Care Benefits segment remained roughly stable year over year on a 30-day-equivalent basis, indicating CVS has largely retained both commercial and Medicare membership despite pricing adjustments and benefit redesigns.
The company’s retail business also continued evolving away from the traditional big-box drugstore format that has become increasingly difficult for competitors to monetize.
CVS said its Pharmacy & Consumer Wellness division continued opening smaller pharmacy-focused locations during the quarter, part of a broader strategic pivot away from the large-format retail model that has weighed heavily on Walgreens Boots Alliance and contributed to the collapse of Rite Aid.
For the broader healthcare industry, the timing is significant.
Healthcare spending remains one of the most durable categories of consumer demand even during economic slowdowns, and aging demographics continue providing long-term structural support for insurers, pharmacies and healthcare-service providers.
But inflation tied to the Iran conflict and global supply-chain disruption is beginning to create new operational pressure points throughout the medical system.
Helium shortages linked to global shipping disruption are now affecting imaging-equipment manufacturers including GE HealthCare, Siemens Healthineers and Philips, because helium remains essential for MRI cooling systems and semiconductor manufacturing used in medical devices.
That pressure is beginning to ripple through hospital purchasing decisions, equipment procurement and insurance reimbursement economics.
For investors, CVS’s report arrives during an unusually fragile moment for the broader managed-care industry.
UnitedHealth Group is still operating under interim leadership following the departure of former CEO Andrew Witty, with chairman Stephen Hemsley overseeing operations temporarily. Humana continues restructuring its Medicare Advantage business, while Centene remains focused on rebuilding profitability inside Medicaid operations.
Against that backdrop, CVS — arguably the most operationally complicated company in the sector because it combines retail pharmacies, insurance, pharmacy-benefit management and primary-care operations under one roof — has now delivered consecutive quarters of improving results.
Wall Street has taken notice.
The stock has rallied roughly 60% from its November 2024 lows, though shares still remain well below their 2022 peak. Analysts at Morgan Stanley, JPMorgan and Bank of America have all upgraded the company over the past six months.
Adding to investor interest, Berkshire Hathaway disclosed a modest CVS position in its most recent 13F filing, fueling speculation that Warren Buffett’s investment team sees value in the company’s recovering cash-flow profile.
The longer-term debate surrounding CVS, however, remains unresolved.
Critics — including lawmakers and policy experts who testified before Congress over the past year — continue arguing that vertically integrated healthcare companies combining insurers, pharmacy-benefit managers and retail pharmacies create conflicts of interest that can ultimately increase drug costs for consumers.
The Federal Trade Commission, now led by Chairman Andrew Ferguson, continues investigating PBM pricing practices initiated under prior agency leadership, while the White House has signaled openness toward additional executive action targeting prescription-drug costs.
For now, though, investors are focused on the numbers in front of them.
CVS Health is once again generating annualized revenue above $400 billion, producing operating cash flow approaching $30 billion, and — for the first time in years — telling Wall Street to raise expectations instead of lower them.
JBizNews Desk
© JBizNews.com. All rights reserved. This article is original reporting by JBizNews Desk. Unauthorized reproduction or redistribution is strictly prohibited.
